"The voice of oncology in Massachusetts."

FDA approves new dosing regimen for pembrolizumab (Keytruda)

April 29, 2020 9:48 AM | Anonymous

The U.S. Food and Drug Administration granted accelerated approval to a new dosing regimen of 400 mg every six weeks for pembrolizumab (KEYTRUDA, Merck) across all currently approved adult indications, in addition to the current 200 mg every three weeks dosing regimen. Read full press release.

Massachusetts Society of Clinical Oncologists ©2023

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  email: msco@mms.org

Powered by Wild Apricot Membership Software